Fatty acid bile acid conjugates inhibit atherosclerosis in the C57BL/6 mouse model

A. Gonen, A. Shaish, A. Leikin-Frenkel, T. Gilat, Dror Harats*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objective: The aim of the current research was to study whether fatty acid bile acid conjugates (FABACs) have a beneficial effect on atherosclerosis progression and blood lipid levels in mice. Methods: C57BL/6 female mice, fed a high-fat Paigen diet, were administered an oral dose of FABAC or DDH2O daily. Quantification of atherosclerotic fatty-streak lesions at the aortic sinus was performed. Results: The FABAC-treated mice showed a significant reduction in the atherosclerotic lesion areas as compared to the control group (p =0.019). A significant elevation in total cholesterol levels was observed in both the FABAC and control groups. Higher FABAC levels were measured in the high-density lipoprotein fraction as compared to the very-low-density and low-density lipoprotein fractions. Conclusion: Our findings demonstrate that FABACs, given orally, reduce the development of atherosclerosis in mice fed a high-fat high-cholesterol diet, despite a lack of effect on plasma lipid levels.

Original languageEnglish
Pages (from-to)215-218
Number of pages4
Issue number4
StatePublished - 2002


  • Atherosclerosis
  • C57BL/6 mice
  • Cholesterol
  • Fatty acid bile acid conjugates


Dive into the research topics of 'Fatty acid bile acid conjugates inhibit atherosclerosis in the C57BL/6 mouse model'. Together they form a unique fingerprint.

Cite this